Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Зипраcидон для внутримышечного введения: опыт и возможности применения в психиатрии

В.Э. Медведев 1, Т.С. Сюняков 2
1 Российский университет дружбы народов, Москва
2 ООО «Пфайзер», Москва

Резюме. В обзоре представлены данные об эффективности современного атипичного антипсихотика зипрасидона для внутримышечного применения при купировании острого психомоторного возбуждения различного генеза (шизофрения, биполярное аффективное расстройство, шизоаффективное расстройство, расстройства импульсивных влечений, алкогольная и другие виды интоксикации), в том числе в случаях недостаточной эффективности других инъекционных антипсихотиков (типичных и атипичных). Незначительная выраженность нежелательных эффектов и сходная эффективность внутримышечного зипрасидона у пациентов различного возраста позволяют применять препарат для купирования возбуждения у детей, подростков и пожилых людей, в том числе соматически неблагополучных. Разработанные схемы перевода больных с лечения зипрасидоном с инъекционной на пероральную форму препарата позволяют обеспечить фармакологическую преемственность терапии без потери эффективности лечения.

Список литературы: 
  • 1. Mautone A., Scarone S., all investigators. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial // Pharmacopsychiatry. – 2011. – Vol. 44, No. 5. – P. 173–178.
  • 2. Bosanac P., Hollander Y., Castle D. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation // Australas Psychiatry. – 2013. – Vol. 21, No. 6. – P. 554–562.
  • 3. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya pomoshch' v psikhiatrii // Neotlozhnaya pomoshch' v meditsinskoi praktike / pod red. A.B. Vertkina, B.S. Briskina. – M.: Litera, 2007. – S. 57–93.
  • 4. Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – 1080 s.
  • 5. Tsukarzi E.E. Neotlozhnaya pomoshch' pri agressivnom povedenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 2. – S. 31–40.
  • 6. Mosolov S.N., Tsukarzi E.E., Alfimov P.V. Algoritmy biologicheskoi terapii shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 1. – S. 27–36.
  • 7. Currier G.W., Trenton A. Pharmacological treatment of psychotic agitation. // CNS Drugs. – 2002. – Vol. 16, No. 4. – P. 219–228.
  • 8. Preval H. et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study // Gen Hosp Psychiatry. –2005. – Vol. 27, No. 2. – P. 140–144.
  • 9. Brook S., Lucey J. V, Gunn K.P. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group // J Clin Psychiatry. – 2000. – Vol. 61, No. 12. – P. 933–941.
  • 10. Medvedev V.E. Lechenie shizofrenii sovremennymi atipichnymi antipsikhoticheskimi preparatami: uchebno-metodich. posobie. – M.: OAO «Konti-Print», 2014. – 72 s.
  • 11. Lesem M.D. et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients // J Clin Psychiatry. – 2001. – Vol. 62, No. 1. – P. 12–18.
  • 12. Nordstrom K., Allen M.H. Managing the acutely agitated and psychotic patient // CNS Spectr. – 2007. – Vol. 12, No. 10, Suppl. 17. – P. 5–11.
  • 13. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – 1080 s.
  • 14. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya terapiya v psikhiatrii // Meditsina kriticheskikh sostoyanii. – 2004. – № 6. – S. 36–41.
  • 15. Chandrasena R. et al. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania // Int J Clin Pract. – 2009. – Vol. 63, No. 8. – P. 1249–1258.
  • 16. Mestre T.A., Zurowski M., Fox S.H. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders // Expert Opin Investig Drugs. – 2013. – Vol. 22, No. 4. – P. 411–421.
  • 17. Morozov P.V. Zeldoks (ziprasidon) – novyi atipichnyi neiroleptik // Psikhiatriya i psikhofarmakoterapiya. – 2005. Vol. 7, No. 5. – P. 264–268.
  • 18. Keck P.E., McElroy S.L. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications // J Clin Psychiatry. – 2002. – Vol. 63, Suppl 4. – P. 3–11.
  • 19. Wilson M.P. et al. Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting // J Emerg Med. – 2013. – Vol. 45, No. 6. – P. 901–908.
  • 20. Nemeroff C.B. et al. From clinical research to clinical practice: a 4-year review of ziprasidone // CNS Spectr. – 2005. – Vol. 10, No. 11, Suppl 17. – P. 1–20.
  • 21. Bykov Yu.V., Bekker R.A., Syunyakov T.S. Ziprasidon: balans mezhdu effektami, effektivnost'yu i perenosimost'yu // Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. – 2016. – № 4. – C. 52–62.
  • 22. Lacroix L.P. et al. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex // Synapse. – 2004. – Vol. 51, No. 2. – P. 158–164.
  • 23. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis // Prog Brain Res. – 2008. – Vol. 172. – P. 199–212.
  • 24. Newman-Tancredi A., Kleven M.S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties // Psychopharmacology (Berl). – 2011. – Vol. 216, No. 4. – P. 451–473.
  • 25. Park S.W. et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats // J Psychiatr Res. – 2009. – Vol. 43, No. 3. – P. 274–281.
  • 26. Kaengkan P. et al. Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats // Mol Cells. – 2013. – Vol. 36, No. 6. – P. 534–541.
  • 27. Benninghoff J. et al. Ziprasidone – Not Haloperidol – Induces more de-novo Neurogenesis of Adult Neural Stem Cells Derived from Murine Hippocampus // Pharmacopsychiatry. – 2012. – Vol. 46, No. 1. – P. 10–15.
  • 28. Rais A.R. et al. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study // Psychiatry (Edgmont). – 2010. – Vol. 7, No. 1. – P. 17–24.
  • 29. Brook S. et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study // Psychopharmacology (Berl). – 2005. – Vol. 178, No. 4. – P. 514–523.
  • 30. Zimbroff D.L. et al. Best clinical practice with ziprasidone IM: update after 2 years of experience // CNS Spectr. – 2005. – Vol. 10, No. 9. – P. 1–15.
  • 31. Weiden P.J. et al. Best clinical practice with ziprasidone: update after one year of experience // J Psychiatr Pract. – 2002. – Vol. 8, No. 2. – P. 81–97.
  • 32. Daniel D.G. et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial // Psychopharmacology (Berl). – 2001. – Vol. 155, No. 2. – P. 128–134.
  • 33. Lesem M.D. et al. Intramuscular Ziprasidone, 2 mg Versus 10 mg, in the Short-Term Management of Agitated Psychotic Patients // J Clin Psychiatry. Physicians Postgraduate Press, Inc. – 2001. – Vol. 62, No. 1. – P. 12–18.
  • 34. Baldaçara L. et al. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone // Rev Bras Psiquiatr. – 2011. – Vol. 33, No. 1. – P. 30–39.
  • 35. Zhang H. et al. Intramuscular Ziprasidone Versus Haloperidol for Managing Agitation in Chinese Patients With Schizophrenia // J Clin Psychopharmacol. – 2013. – Vol. 33, No. 2. – P. 178–185.
  • 36. Brook S. et al. Intramuscular Ziprasidone Compared With Intramuscular Haloperidol in the Treatment of Acute Psychosis // J Clin Psychiatry. – 2000. – Vol. 61, No. 12. – P. 933–941.
  • 37. Martínez-Formoso S. et al. P03-364 Comparison of intramuscular ziprasidone and haloperidol for acute psychotic agitation in an emergency room // Eur Psychiatry. – 2010. – Vol. 25.
  • 38. Fulton J.A. et al. Intramuscular ziprasidone: an effective agent for sedation of the agitated ED patient // Am J Emerg Med. – 2006. – Vol. 24, No. 2. – P. 254–255.
  • 39. Syunyakov T.S. Molekulyarnaya genetika i farmakogenetika bipolyarnogo affektivnogo rasstroistva // Psikhiatriya. – 2014. – T. 63, № 3. – C. 73–87.
  • 40. Citrome L. et al. Efficacy of Ziprasidone Against Hostility in Schizophrenia: Post Hoc Analysis of Randomized, Open-Label Study Data // J Clin Psychiatry. – 2006. – Vol. 67, No. 4. –P. 638–642.
  • 41. Swift R.H. et al. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients // J Psychiatr Res. – Vol. 36, No. 2. – P. 87–95.
  • 42. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale // Psychol Rep. – 1962. – Vol. 10, No. 3. – P. 799–812.
  • 43. Battaglia J. et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study // Am J Emerg Med. – 1997. – Vol. 15, No. 4. – P. 335–340.
  • 44. Citrome L. Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation: A Quantitative Review of Efficacy and Safety // J Clin Psychiatry. – 1876. – Vol. 68. – P. 1876–1885.
  • 45. Barak Y. et al. Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia // Am J Geriatr Psychiatry. – 2006. – Vol. 14, No. 7. – P. 629–633.
  • 46. Kohen I. et al. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service // Am J Geriatr Pharmacother. – 2005. –Vol. 3, No. 4. – P. 240–245.
  • 47. Jangro W.C. et al. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study // Child Adolesc Psychiatry Ment Health. – 2009. – Vol. 3, No. 1. – P. 9.
  • 48. Barzman D.H. et al. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed // J Child Adolesc Psychopharmacol. – 2007. – Vol. 17, No. 4. – P. 503–509.
  • 49. Staller J.A. Intramuscular ziprasidone in youth: a retrospective chart review. // J Child Adolesc Psychopharmacol. – 2004. – Vol. 14, No. 4. – P. 590–592.
  • 50. Khan S.S., Mican L.M. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents // J Child Adolesc Psychopharmacol. – 2006. – Vol. 16, No. 6. – P. 671–677.
  • 51. Hazaray E. et al. Intramuscular ziprasidone for acute agitation in adolescents. // J Child Adolesc Psychopharmacol. – 2004. – Vol. 14, No. 3. – P. 464–470.
  • 52. Daniel D.G. Tolerability of ziprasidone: an expanding perspective // J Clin Psychiatry. – 2003. – Vol. 64, Suppl 1. – P. 40–49.
  • 53. Leung J.G. et al. Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost // Am J Ther. – 2011. – Vol. 18, No. 4. – P. 300–304.
  • 54. Cañas F. et al. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial // Clin Drug Investig. – 2007. – Vol. 27, No. 9. – P. 633–645.
  • 55. Baptista T. et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics // Curr Drug Targets. – 2004. – Vol. 5, No. 3. – P. 279–299.
  • 56. Mosolov S.N., Ryvkin P.V., Serditov O.V., Ladyzhenskii M.Ya., Potapov A.V. Metabolicheskie pobochnye effekty sovremennoi antipsikhoticheskoi farmakoterapii // Sotsial'naya i klinicheskaya psikhiatriya. – 2008. – T. 18, № 3. – S. 75–90.
  • 57. Alfimov P.V., Ryvkin P.V., Ladyzhenskii M.Ya., Mosolov S.N. Metabolicheskii sindrom u bol'nykh shizofreniei // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2014. – № 3. – S. 8–14.
  • 58. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function // CNS Drugs. – 2002. – Vol. 16, No. 1. – P. 23–45.
  • 59. Miodownik C. et al. Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients // Clin Neuropharmacol. – Vol. 28, No. 6. – P. 295–297.